From Our 2010 Archives
New Hormonal Contraceptive Approved
Latest Sexual Health News
THURSDAY, May 6 (HealthDay News) -- The Bayer Healthcare Pharmaceuticals combination hormonal contraceptive Natazia has been approved by the U.S. Food and Drug Administration.
The tablet combines two female hormones, estrogen and progestin, and is meant to deliver doses four times during its 28-day treatment cycle, the FDA said in a news release.
The drug was evaluated by more than 1,800 women during clinical testing in North America and Europe. The most common adverse effects were irregular bleeding, breast tenderness, headache, nausea and vomiting, weight gain and acne.
Women who smoke while taking the drug are at greater risk of serious cardiovascular problems. Women older than 35 who smoke should not use the product, the agency warned.
Bayer is based in Wayne, N.J.
-- Scott Roberts
Copyright © 2010 HealthDay. All rights reserved.
- Allergic Skin Disorders
- Bacterial Skin Diseases
- Bites and Infestations
- Diseases of Pigment
- Fungal Skin Diseases
- Medical Anatomy and Illustrations
- Noncancerous, Precancerous & Cancerous Tumors
- Oral Health Conditions
- Papules, Scales, Plaques and Eruptions
- Scalp, Hair and Nails
- Sexually Transmitted Diseases (STDs)
- Vascular, Lymphatic and Systemic Conditions
- Viral Skin Diseases
- Additional Skin Conditions